Daily Bio News Summary — 2026-07-17: GSK Bellus cough fails, Celcuity Revtorpyk wins, IPO window stays hot

The 9 AM PT biopharma news harvest for Friday, July 17, 2026, captured ~50 fresh articles across BioSpace, Fierce Pharma, Fierce Biotech, STAT News, Endpoints News, BioPharma Dive, Pharmaphorum, FDA Newsroom, and PR Newswire. The day’s headlines skew heavily toward M&A, IPO filings, and clinical/regulatory readouts — a continuation of the Q3-2026 pattern of capital-markets velocity.

M&A and capital markets

The day’s headline deal is Lilly’s $2.8B AtaiBeckley acquisition, covered across at least 5 outlets (Endpoints News, Fierce Biotech, Fierce Pharma, BioPharma Dive, MedCity News). It is the largest psychedelics-focused pharma buyout to date and Lilly’s 12th M&A deal of 2026 (Endpoints News, Fierce Biotech, MedCity News). The buyout validates the psychedelics therapeutic class after years of skepticism (BioPharma Dive).

Dimerix bought Mission Therapeutics’ kidney-injury drug for $292M (Fierce Biotech, Endpoints News, Pharmaphorum). Mission Therapeutics, a UK-based USP30 specialist, is sharpening its focus on CNS after the divestiture (Pharmaphorum).

IPO filings accelerated: Braveheart, Attovia, and BlossomHill Therapeutics all filed this week (Endpoints News, BioSpace, BioPharma Dive). BlossomHill is chasing AstraZeneca’s Tagrisso in EGFR-mutant NSCLC. The IPO tracker says six drug startups have entered the queue in July alone (BioPharma Dive). Braveheart’s program is a Hengrui-licensed rival to Cytokinetics.

Smaller financings: AdvanCell raised $315M for a Pluvicto challenger in radiopharma (Endpoints News, Pharmaphorum); Nava Therapeutics emerged with $89M for lipid nanoparticles (Endpoints News); Chai Discovery tripled its valuation with a $400M round (Endpoints News); Draig raised $65M for synapse-rebuilding depression drug (Endpoints News).

Clinical and regulatory readouts

Celcuity gained FDA approval for Revtorpyk (gedatolisib) in HR+/HER2- breast cancer — a first-in-class PI3K inhibitor (BioPharma Dive, MedCity News). Insmed posted long-term durability data on TPIP for PAH that supports a $6B opportunity (BioSpace). Merck won FDA approval for the first oral PCSK9 inhibitor (enlicitide/Lipfrendra) (BioPharma Dive). Merck’s sac-TMT ADC also showed potential to replace chemo in lung cancer in a China Phase 3 (BioPharma Dive).

GSK culled its chronic cough drug from the $2B Bellus Health acquisition after Phase 3 failure — covered across BioSpace, Fierce Biotech, Endpoints News, and Pharmaphorum. Takeda reported “top-notch” Phase 3 data for zasocitinib in hard-to-treat psoriasis (Fierce Biotech). AstraZeneca + Ionis’s eplontersen (Wainua) failed Phase 3 in ATTR cardiomyopathy (MedCity News).

Biogen’s tau-targeting antisense drug diranersen drew a “promise + questions” frame at AAIC 2026 (BioPharma Dive, BioSpace, STAT News). GSK launched a large study to test whether the shingles vaccine can prevent dementia (Endpoints News).

FDA program news: first AI-focused cGMP warning letter (BioSpace); EUA for a New World Screwworm drug in horses (FDA Newsroom, July 15). PR Newswire FDA approvals: LUMVOA (veligrotug-vvze) for thyroid eye disease (Jul 16); Camurus’ NDA resubmission for CAM2029 in acromegaly (Jul 17). Camurus’ ticker is NASDAQ STO: CAMX.

Public-market and policy noise

FDA formally disavowed papers authored by Makary and Prasad as a lawmaker blasted “shoot-from-the-hip” policymaking (BioSpace). The Bipartisan Senate bill targeting foreign drugmakers (Fierce Pharma) signals policy risk for Indian and Chinese CDMOs. Pete Hegseth’s annual testosterone screening proposal for service members divided medical experts (STAT News). Vanda launched a Schumacher IndyCar sponsorship (Fierce Pharma).

What this batch is NOT telling us

• AI-bio clinical readouts — only generic “AI drugs in the clinic” framing (BioPharma Dive). No individual company-specific Phase 2/3 AI-designed molecule readouts today.
• Insulin / pricing / IRA — CVS Caremark/FTC insulin settlement (BioPharma Dive) is the only pricing-related story. The IRA drug-negotiation pipeline is silent today.
• Megacap pharma earnings — J&J’s Q2 results dipped despite an upbeat outlook (BioPharma Dive); Lilly’s Buyout-spree continues but no earnings today.

Reading order (top 5)

1. Lilly’s $2.8B AtaiBeckley buyout — field-shaping for the psychedelics class (Endpoints News)
2. Celcuity’s Revtorpyk FDA approval — first-in-class for HR+/HER2- breast cancer (BioPharma Dive)
3. GSK culls chronic cough drug — the $2B Bellus buyout’s lead asset fails Phase 3 (BioSpace)
4. Merck’s oral PCSK9 wins FDA — first oral in the PCSK9 class (BioPharma Dive)
5. Biotech IPO window keeps ballooning — 6 drug startups in July alone (BioPharma Dive IPO tracker)

How to read the underlying articles

Each item above links to the corresponding file in src/content/news/. Frontmatter sourceUrl and sourceName give the canonical source; pubDate is in YYYY-MM-DD form. Company-specific items also carry a companyId field matching the kebab-case slug under src/content/companies/.

Today’s items (numbered list)

1. 2026 IPO stock tracker: How biotechs new to public markets are performing — BioSpace, 2026-07-17
2. GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail — BioSpace, 2026-07-17
3. Insmed moves closer to $6B opportunity as PAH drug shows long-term durability — BioSpace, 2026-07-17
4. FDA disavows Makary, Prasad’s papers as lawmaker blasts ‘shoot-from-the-hip’ policymaking — BioSpace, 2026-07-16
5. FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers — BioSpace, 2026-07-16
6. AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug — BioSpace, 2026-07-15
7. BIO 2026: As ADCs evolve, experts say ‘wellness’ needs to be factored into patient survival — BioSpace, 2026-07-13
8. The future of pain relief: Exploring opioid alternatives — BioSpace, 2026-07-14
9. Report: Biopharma Job Market Report Q2 2026 — BioSpace, 2026-07-13
10. Bipartisan bill targets foreign drugmaking in US — Fierce Pharma, 2026-07-16
11. Huahai poaches quality chief from Hengrui amid FDA citations — Fierce Pharma, 2026-07-16
12. Foundation Medicine starts push to stand out in cancer testing — Fierce Pharma, 2026-07-17
13. CG Life film festival gives rare diseases a starring role — Fierce Pharma, 2026-07-16
14. Vanda shifts into high gear with Schumacher IndyCar sponsorship — Fierce Pharma, 2026-07-16
15. GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia — Fierce Pharma, 2026-07-17
16. Novo, Alvotech written up after FDA site inspections — Fierce Pharma, 2026-07-17
17. The Oral GLP-1 Tracker: Lilly’s Foundayo scripts tick up — Fierce Pharma, 2026-07-17
18. Jasper merges with Kira, while Tavneos rival sent to Mirador — Fierce Biotech, 2026-07-17
19. 5 emerging biotech hubs — Fierce Biotech, 2026-07-17
20. Cue lines up new CMO and research head—Chutes & Ladders — Fierce Biotech, 2026-07-17
21. GSK axes key cough drug candidate after phase 3 data disappoint — Fierce Biotech, 2026-07-17
22. Dimerix buys Mission’s kidney disease prospect in $292M deal — Fierce Biotech, 2026-07-17
23. Takeda’s zasocitinib ‘top-notch’ for hard-to-treat psoriasis — Fierce Biotech, 2026-07-16
24. Nobel Laureate Jennifer Doudna enters AI protein design arena — Fierce Biotech, 2026-07-16
25. Can the shingles vaccine prevent Alzheimer’s? GSK has a big study to find out — Endpoints News, 2026-07-17
26. Tagrisso-chasing BlossomHill enters Nasdaq queue as biotech IPOs flourish — Endpoints News, 2026-07-17
27. Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire — Endpoints News, 2026-07-17
28. ‘We’re paranoid.’ As China biotech competition heats up, American drugmakers get more secretive — Endpoints News, 2026-07-11
29. Dimerix buys a kidney injury drug; Arpeggio appears to be winding down — Endpoints News, 2026-07-17
30. GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyout — Endpoints News, 2026-07-17
31. Mirador unveils a piece of pipeline with drug from Kira to rival troubled Tavneos — Endpoints News, 2026-07-17
32. Eli Lilly invests in Oura to support patients on GLP-1 drugs — Endpoints News, 2026-07-16
33. Updated: Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger — Endpoints News, 2026-07-16
34. Exclusive: Lipid nanoparticle startup Nava emerges with $89M to target T cells and kidney — Endpoints News, 2026-07-15
35. Braveheart files for IPO to fund Phase 3 of Hengrui’s Cytokinetics rival — Endpoints News, 2026-07-15
36. Chai Discovery gets $400M, tripling valuation from seven months ago — Endpoints News, 2026-07-14
37. Draig nets $65M to advance depression drug aimed at rebuilding synapses — Endpoints News, 2026-07-14
38. Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley — Endpoints News, 2026-07-16
39. I&I startup Attovia files to go public as biotech listings momentum builds — Endpoints News, 2026-07-15
40. Post-Hoc Live: What’s making biotech IPOs work again? — Endpoints News, 2026-07-15
41. Lettuce at Taco Bell in five states confirmed as a source of diarrhea-causing parasite — STAT News, 2026-07-17
42. MAHA is rewriting the vocabulary of American mental health care — STAT News, 2026-07-17
43. Can ultrasound unlock the power of gene therapy? A startup makes big claims — STAT News, 2026-07-17
44. Predicting biotech clinical trials and a new Alzheimer’s drug controversy — STAT News, 2026-07-16
45. Pete Hegseth’s announcement of annual testosterone screenings for service members divides medical experts — STAT News, 2026-07-16
46. How well are AI-discovered drugs faring in the clinic? — BioPharma Dive, 2026-07-16
47. Merck wins first approval of a PCSK9 cholesterol pill — BioPharma Dive, 2026-07-15
48. Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss — BioPharma Dive, 2026-07-15
49. Merck ADC, in China study, shows potential to replace chemo in lung cancer — BioPharma Dive, 2026-07-16
50. Celcuity gains FDA approval for closely watched breast cancer drug — BioPharma Dive, 2026-07-15
51. Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs — BioPharma Dive, 2026-07-15
52. 10 clinical trials to watch in the second half of 2026 — BioPharma Dive, 2026-07-14
53. UK experts call for meningitis shots for all 15-year-olds — Pharmaphorum, 2026-07-16
54. UK’s Mission divests kidney drug to Dimerix for $292m — Pharmaphorum, 2026-07-17
55. Camurus’ NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA — PR Newswire FDA, 2026-07-17
56. Raymond Douglas, MD, PhD, is first in the nation to infuse newly FDA-approved thyroid eye disease treatment LUMVOA — PR Newswire FDA, 2026-07-16